康宁杰瑞生物医药（09966）于2026年2月5日公布截至2026年1月31日止的月度证券变动报告。报告显示，公司本月内未有新增发行、购回或注销股份，股本结构保持稳定。
公司法定注册股本仍为25,100,000,000股普通股，面值USD 0.000002，每股面值总额USD 50,200，与上月一致。已发行股份（不含库存股）为968,574,697股，库存股数量为5,719,000股，合计974,293,697股，均无变动。
期权与激励方面，本月未发生行使、授出或失效。各项已授出的前后购股权数量保持不变，公司确认已遵守香港联合交易所有限公司《上市规则》及相关法律规定。
本次月报由公司执行董事徐霆签署并提交。公司表示，截至2026年1月31日，整体股本维持不变，符合相关上市规则对公众持股量的要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.